Light Mode
$577.33 ↓ -31.16 (-5.12%) Trading Down from the previous close of $608.49, $30.96 below the day’s high of $608.29
+36.29 (+6.34%) / 6M
Momentum, market sentiment, and recent alerts
UTHR reads neutral: price sits above both the 20- and 200-day averages, the 12-month move is +36.0%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.